Seeking Alpha

Oxigene (OXGN) soars 34% after saying its Zybrestat treatment for ovarian cancer was well...

Oxigene (OXGN) soars 34% after saying its Zybrestat treatment for ovarian cancer was well tolerated when used in conjunction with Roche's Avastin in a Phase II trial, with no additional safety concerns. Oxigene expects patient accrual for the study to be completed within the next 3-4 months and for top-line data to be available at the end of the year. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs